Search Results - "Noopur, Raje"

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma by Munshi, Nikhil C, Anderson, Larry D, Shah, Nina, Madduri, Deepu, Berdeja, Jesús, Lonial, Sagar, Raje, Noopur, Lin, Yi, Siegel, David, Oriol, Albert, Moreau, Philippe, Yakoub-Agha, Ibrahim, Delforge, Michel, Cavo, Michele, Einsele, Hermann, Goldschmidt, Hartmut, Weisel, Katja, Rambaldi, Alessandro, Reece, Donna, Petrocca, Fabio, Massaro, Monica, Connarn, Jamie N, Kaiser, Shari, Patel, Payal, Huang, Liping, Campbell, Timothy B, Hege, Kristen, San-Miguel, Jesús

“…Autologous T cells engineered to express a chimeric antigen receptor specific for the B-cell maturation antigen produced responses in the majority of patients…”
Get full text

Role of the RANK/RANKL Pathway in Multiple Myeloma by Raje, Noopur S, Bhatta, Sumita, Terpos, Evangelos

“…Receptor activator of nuclear factor-kappa B (RANK) and its ligand, RANKL, are expressed in a variety of tissues throughout the body; their primary role is in…”
Get full text

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma by Raje, Noopur, Berdeja, Jesus, Lin, Yi, Siegel, David, Jagannath, Sundar, Madduri, Deepu, Liedtke, Michaela, Rosenblatt, Jacalyn, Maus, Marcela V, Turka, Ashley, Lam, Lyh-Ping, Morgan, Richard A, Friedman, Kevin, Massaro, Monica, Wang, Julie, Russotti, Greg, Yang, Zhihong, Campbell, Timothy, Hege, Kristen, Petrocca, Fabio, Quigley, M. Travis, Munshi, Nikhil, Kochenderfer, James N

“…Chimeric antigen receptor autologous T cells that were directed against the B-cell maturation antigen induced responses in 85% of the 33 patients with relapsed…”
Get full text

Panobinostat and Multiple Myeloma in 2018 by Yee, Andrew J., Raje, Noopur S.

“…FDA and EMA approval of panobinostat offers an additional therapeutic option for multiple myeloma; however, adoption of panobinostat has been limited by its…”
Get full text

Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma by Vogl, Dan T, Raje, Noopur, Jagannath, Sundar, Richardson, Paul, Hari, Parameswaran, Orlowski, Robert, Supko, Jeffrey G, Tamang, David, Yang, Min, Jones, Simon S, Wheeler, Catherine, Markelewicz, Robert J, Lonial, Sagar

“…Histone deacetylase (HDAC) inhibition improves the efficacy of proteasome inhibition for multiple myeloma but adds substantial toxicity. Preclinical models…”
Get full text

Advances in the biology and treatment of bone disease in multiple myeloma by Raje, Noopur, Roodman, G David

“…Osteolytic bone disease is pathognomonic of multiple myeloma (MM) and affects more than 80% of patients. Bone disease results in skeletal-related events (SRE)…”
Get full text

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma by Richardson, Paul G., Jacobus, Susanna J., Weller, Edie A., Hassoun, Hani, Lonial, Sagar, Raje, Noopur S., Medvedova, Eva, McCarthy, Philip L., Libby, Edward N., Voorhees, Peter M., Orlowski, Robert Z., Anderson, Larry D., Zonder, Jeffrey A., Milner, Carter P., Gasparetto, Cristina, Agha, Mounzer E., Khan, Abdullah M., Hurd, David D., Gowin, Krisstina, Kamble, Rammurti T., Jagannath, Sundar, Nathwani, Nitya, Alsina, Melissa, Cornell, R. Frank, Hashmi, Hamza, Campagnaro, Erica L., Andreescu, Astrid C., Gentile, Teresa, Liedtke, Michaela, Godby, Kelly N., Cohen, Adam D., Openshaw, Thomas H., Pasquini, Marcelo C., Giralt, Sergio A., Kaufman, Jonathan L., Yee, Andrew J., Scott, Emma, Torka, Pallawi, Foley, Amy, Fulciniti, Mariateresa, Hebert, Kyle, Samur, Mehmet K., Masone, Kelly, Maglio, Michelle E., Zeytoonjian, Andrea A., Nadeem, Omar, Schlossman, Robert L., Laubach, Jacob P., Paba-Prada, Claudia, Ghobrial, Irene M., Perrot, Aurore, Moreau, Philippe, Avet-Loiseau, Hervé, Attal, Michel, Anderson, Kenneth C., Munshi, Nikhil C.

“…In a large, multinational, randomized trial, continuous lenalidomide maintenance therapy after triplet therapy (lenalidomide, bortezomib, and dexamethasone)…”
Get full text

Cyclin dependent kinases in cancer: Potential for therapeutic intervention by Canavese, Miriam, Santo, Loredana, Raje, Noopur

“…Cell cycle progression through each phase is regulated by heterodimers formed by cyclin-dependent kinases (CDKs) and their regulatory partner proteins, the…”
Get full text

Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline by Mikhael, Joseph, Ismaila, Nofisat, Cheung, Matthew C, Costello, Caitlin, Dhodapkar, Madhav V, Kumar, Shaji, Lacy, Martha, Lipe, Brea, Little, Richard F, Nikonova, Anna, Omel, James, Peswani, Namrata, Prica, Anca, Raje, Noopur, Seth, Rahul, Vesole, David H, Walker, Irwin, Whitley, Alexander, Wildes, Tanya M, Wong, Sandy W, Martin, Tom

“…To provide evidence-based recommendations on the treatment of multiple myeloma to practicing physicians and others. ASCO and Cancer Care Ontario convened an…”
Get full text

Monoclonal Antibodies in Multiple Myeloma Come of Age by Raje, Noopur, Longo, Dan L

“…Multiple myeloma is a cancer of plasma cells that has an estimated incidence of 26,850 new patients in 2015 in the United States. 1 In the past few years,…”
Get full text

Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group by Terpos, Evangelos, Zamagni, Elena, Lentzsch, Suzanne, Drake, Matthew T, García-Sanz, Ramón, Abildgaard, Niels, Ntanasis-Stathopoulos, Ioannis, Schjesvold, Fredrik, de la Rubia, Javier, Kyriakou, Charalampia, Hillengass, Jens, Zweegman, Sonja, Cavo, Michele, Moreau, Philippe, San-Miguel, Jesus, Dimopoulos, Meletios A, Munshi, Nikhil, Durie, Brian G M, Raje, Noopur

“…In this Policy Review, the Bone Working Group of the International Myeloma Working Group updates its clinical practice recommendations for the management of…”
Get full text

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders by Hillengass, Jens, Usmani, Saad, Rajkumar, S Vincent, Durie, Brian G M, Mateos, María-Victoria, Lonial, Sagar, Joao, Cristina, Anderson, Kenneth C, García-Sanz, Ramón, Riva, Eloísa, Du, Juan, van de Donk, Niels, Berdeja, Jesús G, Terpos, Evangelos, Zamagni, Elena, Kyle, Robert A, San Miguel, Jesús, Goldschmidt, Hartmut, Giralt, Sergio, Kumar, Shaji, Raje, Noopur, Ludwig, Heinz, Ocio, Enrique, Schots, Rik, Einsele, Hermann, Schjesvold, Fredrik, Chen, Wen-Ming, Abildgaard, Niels, Lipe, Brea C, Dytfeld, Dominik, Wirk, Baldeep Mona, Drake, Matthew, Cavo, Michele, Lahuerta, Juan José, Lentzsch, Suzanne

“…Recent advances in the treatment of multiple myeloma have increased the need for accurate diagnosis of the disease. The detection of bone and bone marrow…”
Get full text

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations by Hyman, David M, Puzanov, Igor, Subbiah, Vivek, Faris, Jason E, Chau, Ian, Blay, Jean-Yves, Wolf, Jürgen, Raje, Noopur S, Diamond, Eli L, Hollebecque, Antoine, Gervais, Radj, Elez-Fernandez, Maria Elena, Italiano, Antoine, Hofheinz, Ralf-Dieter, Hidalgo, Manuel, Chan, Emily, Schuler, Martin, Lasserre, Susan Frances, Makrutzki, Martina, Sirzen, Florin, Veronese, Maria Luisa, Tabernero, Josep, Baselga, José

“…In a basket trial that included patients with a variety of cancers, all of which contained a BRAF V600 mutation, the rate of response to vemurafenib was highly…”
Get full text

In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells by CHAUHAN, Dharminder, ZE TIAN, BIN ZHOU, KUHN, Deborah, ORLOWSKI, Robert, RAJE, Noopur, RICHARDSON, Paul, ANDERSON, Kenneth C

“…The success of bortezomib therapy for treatment of multiple myeloma (MM) led to the development of structurally and pharmacologically distinct novel proteasome…”
Get full text

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial by Bahlis, Nizar J., Costello, Caitlin L., Raje, Noopur S., Levy, Moshe Y., Dholaria, Bhagirathbhai, Solh, Melhem, Tomasson, Michael H., Damore, Michael A., Jiang, Sibo, Basu, Cynthia, Skoura, Athanasia, Chan, Edward M., Trudel, Suzanne, Jakubowiak, Andrzej, Gasparetto, Cristina, Chu, Michael P., Dalovisio, Andrew, Sebag, Michael, Lesokhin, Alexander M.

“…Multiple myeloma (MM) is a plasma cell malignancy expressing B cell maturation antigen (BCMA). Elranatamab, a bispecific antibody, engages BCMA on MM and CD3…”
Get full text

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial by Yee, Andrew J, MD, Bensinger, William I, MD, Supko, Jeffrey G, PhD, Voorhees, Peter M, MD, Berdeja, Jesus G, MD, Richardson, Paul G, Prof, Libby, Edward N, MD, Wallace, Ellen E, BA, Birrer, Nicole E, BA, Burke, Jill N, MSN, Tamang, David L, PhD, Yang, Min, PhD, Jones, Simon S, PhD, Wheeler, Catherine A, MD, Markelewicz, Robert J, MD, Raje, Noopur S, Dr

“…Summary Background Histone deacetylase (HDAC) inhibitors are an important new class of therapeutics for treating multiple myeloma. Ricolinostat (ACY-1215) is…”
Get full text

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma by Mikhael, Joseph, Richardson, Paul, Usmani, Saad Z., Raje, Noopur, Bensinger, William, Karanes, Chatchada, Campana, Frank, Kanagavel, Dheepak, Dubin, Franck, Liu, Qianying, Semiond, Dorothée, Anderson, Kenneth

“…This phase 1b dose-escalation study evaluated isatuximab plus pomalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). Patients…”
Get full text

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial by Lin, Yi, Raje, Noopur S., Berdeja, Jesús G., Siegel, David S., Jagannath, Sundar, Madduri, Deepu, Liedtke, Michaela, Rosenblatt, Jacalyn, Maus, Marcela V., Massaro, Monica, Petrocca, Fabio, Yeri, Ashish, Finney, Olivia, Caia, Andrea, Yang, Zhihong, Martin, Nathan, Campbell, Timothy B., Rytlewski, Julie, Fuller, Jaymes, Hege, Kristen, Munshi, Nikhil C., Kochenderfer, James N.

“…Idecabtagene vicleucel (ide-cel) is a B-cell-maturation antigen (BCMA)-directed chimeric antigen receptor T cell therapy. We performed a post hoc analysis of a…”
Get full text

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myeloma by O'Donnell, Elizabeth K., Laubach, Jacob P., Yee, Andrew J., Chen, Tianqi, Huff, Carol Ann, Basile, Frank G., Wade, Philip M., Paba‐Prada, Claudia E., Ghobrial, Irene M., Schlossman, Robert L., Burke, Jill N., Harrington, Cynthia C., Lively, Kathleen J., Lyons, Hannah F., Munshi, Nikhil C., Anderson, Kenneth C., Trippa, Lorenzo, Richardson, Paul G., Raje, Noopur S.

“…We sought a regimen that incorporates optimal novel agents and balances efficacy with toxicity in transplant‐ineligible multiple myeloma (MM) patients. Our…”
Get full text

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans by Görgün, Güllü Topal, Whitehill, Gregory, Anderson, Jennifer L., Hideshima, Teru, Maguire, Craig, Laubach, Jacob, Raje, Noopur, Munshi, Nikhil C., Richardson, Paul G., Anderson, Kenneth C.

“…Myeloid-derived suppressor cells (MDSCs) are a heterogeneous, immature myeloid cell population with the ability to suppress immune responses. MDSCs have been…”
Get full text